VTRS - Viatris Inc

Viatris is a global healthcare company that integrates the strengths of both branded and generic pharmaceuticals to meet diverse healthcare needs. Founded from the merger of Mylan and Pfizer's Upjohn, the company boasts a vast portfolio of over 1,400 approved molecules targeting various therapeutic areas, including a strong focus on chronic, non-communicable diseases, infectious diseases, and complex drug formulations. With a manufacturing presence in approximately 40 sites worldwide, Viatris ensures the distribution of high-quality medicines across more than 165 countries, aiming to improve patient access at scale.

The company operates under a unique business model that combines cost-effective generics and valuable branded products, bolstered by a significant investment in Research and Development (R&D) to enhance its pipeline of innovative therapies. As Viatris transitions through its strategic phases, it aims to simplify operations, divest less profitable sectors, and invest in high-margin segments like complex and novel products. This roadmap highlights Viatris's commitment to delivering sustainable value to all stakeholders, including patients, healthcare systems, and shareholders.